Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis
- 1 December 1994
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (12) , 2750-2757
- https://doi.org/10.1128/aac.38.12.2750
Abstract
The pneumocandins are natural lipopeptide products of the echinocandin class which inhibit the synthesis of 1,3-beta-D-glucan in susceptible fungi. The lack of a corresponding pathway in mammalian hosts makes this mode of action an attractive one for treating systemic infections. Substitution by an aminoethyl ether at the hemiaminal and dehydration and reduction of the glutamine of pneumocandin B0 produced a semisynthetic compound (L-733,560) with intrinsic water solubility, significantly increased potency, and a broader antifungal spectrum. To evaluate the mechanism for the improved antifungal efficacy, we determined that L-733,560 was a more potent inhibitor of glucan synthase activity in vitro, did not affect the other membrane-bound enzymes tested, conferred susceptibility to lysis in the absence of osmotic support, and did not disrupt currents in liposomal bilayers or 86Rb+ fluxes from liposomes. In Aspergillus species L-733,560 also produced the same morphological alterations as pneumocandin B0. A stereoisomer of L-733,560 with poor antifungal activity was a weak inhibitor of glucan synthase. All of these results support the notion that the enhanced antifungal activity of L-733,560 is achieved by superior inhibition of glucan synthesis and not by nonspecific membrane effects or a second mode of action.Keywords
This publication has 28 references indexed in Scilit:
- Synthesis and Antifungal Activity of Novel Cationic Pneumocandin Bo DerivativesJournal of Medicinal Chemistry, 1994
- A kinetic study on the regeneration ofCandida albicansprotoplasts in the presence of cell wall synthesis inhibitorsFEMS Microbiology Letters, 1993
- Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP)Journal of Medicinal Chemistry, 1992
- The function of chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle.The Journal of cell biology, 1991
- Synthesis and Evaluation of LY121019, a Member of a Series of Semisynthetic Analogues of the Antifungal Lipopeptide Echinocandin BaAnnals of the New York Academy of Sciences, 1988
- Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activityAntimicrobial Agents and Chemotherapy, 1988
- Anti-Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal AntibioticAnnals of the New York Academy of Sciences, 1988
- The effect of aculeacin A and papulacandin B on morphology and cell wall ultrastructure in Candida albicansCanadian Journal of Microbiology, 1984
- Papulacandin B: an Inhibitor of Glucan Synthesis in Yeast SpheroplastsEuropean Journal of Biochemistry, 1979
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976